Abrocitinib is an oral medication that effectively treats moderate-to-severe atopic dermatitis in adults and adolescents aged 12 and older. Clinical trials showed significant improvements in skin clearance and itch reduction compared to placebo, with effects seen as early as 2 weeks after starting treatment.
-
Effective treatment of oral lichen planus with the JAK inhibitor baricitinib
Effective treatment of oral lichen planus with the JAK inhibitor baricitinib
Anthony Moussa, Themis Colla, Brendan Morrison, Rodney Sinclair
DOI: 10.1111/ajd.13811
None
•
None participants
•
2022
•
6 citations
-
What is this paper about?
-
What populations did the authors study?
Not available patients. With moderate to severe eczema. Patients are 12+. Having taken the following prior treatments: inadequate response to topical prescription therapies.
-
What did the authors find?
Analyzing metric: IGA.
Findings show: Invervention leads to not available.
Resulting in: Significantly more patients achieved clear or almost clear skin with abrocitinib compared to placebo.
Analyzing metric: EASI-75.
Findings show: Invervention leads to not available.
Resulting in: Significantly more patients achieved 75% improvement in their eczema with abrocitinib compared to placebo. -
What conclusions can we draw?
nan
